T0	Outcomes 262 296	efficacy, safety, and tolerability
T1	Outcomes 870 949	American College of Rheumatology 20% improvement criteria (ACR20) response rate
T2	Outcomes 982 987	ACR20
T3	Outcomes 1321 1358	the ACR20, ACR50, and ACR70 responses
T4	Outcomes 1371 1558	the Health Assessment Questionnaire disability index, the 3-variable Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP), and a 3-variable DAS28-CRP of <2.6
T5	Outcomes 1576 1609	treatment-emergent adverse events
T6	Outcomes 1665 1728	were diarrhea, upper respiratory tract infection, and headache;
T7	Outcomes 1748 1782	experienced serious adverse events
T8	Outcomes 1793 1879	increases in transaminase levels, increases in cholesterol and serum creatinine levels
T9	Outcomes 1885 1930	decreases in neutrophil and hemoglobin levels